恒瑞医药帕立骨化醇软胶囊获批上市

Core Viewpoint - Heng Rui Medicine announced the approval of its subsidiary Chengdu Shengdi Pharmaceutical's paricalcitol soft capsules by the National Medical Products Administration for the treatment of secondary hyperparathyroidism in adults with chronic kidney disease stages 3-4 [1] Group 1 - The approved indication for the drug is to prevent and treat secondary hyperparathyroidism in adults with chronic kidney disease [1]